GSK Stock Recent News

GSK has hailed the results from a late-stage trial of a new oral antibiotic for gonorrhoea, which met its primary endpoint of at last matching the current standard treatments. Chris Corsico, senior vice president, development, at GSK, said: “With rising incidence rates and concern around growing resistance to existing treatments, gonorrhoea poses a threat to public health globally.

Here is how GSK (GSK) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

British drugmaker GSK said on Monday its oral gonorrhoea drug met its primary goal of non-inferiority in a late-stage trial, compared to an existing combination treatment.

Moderna (NASDAQ: MRNA) stock significantly surged on February 22 after the company surpassed Wall Street's quarterly expectations.

Good dividend stocks provide their owners with reliable income. What's more, even if these equities drop, investors are “paid to wait” for them to rebound down the road.

British pharma giant GSK on Wednesday announced promising results for a long-acting injectable HIV therapy, offering a hopeful alternative for people who take daily pills to halt the virus's progression.

British drugmaker GSK said on Wednesday its long-acting injectable HIV therapy showed promise in keeping the viral load suppressed compared to daily oral treatment, especially in individuals facing challenges with pill intake.

GSK PLC (LSE:GSK, NYSE:GSK) has announced the US$1.4 billion acquisition of respiratory biopharmaceuticals firm Aiolos Bio. FTSE 100-listed GSK said the takeover, which will se US$1 billion paid upfront followed by a further US$400 million in performance-linked payments, would offer it access to Aiolos' long-acting anti-thymic stromal lymphopoietin (TSLP) treatment.

GSK said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions.

The healthcare team at Citi has turned positive on GSK PLC (LSE:GSK, NYSE:GSK) for the first time in seven years. Pushing the investment bank's analysts over the precipice to 'buy' was the outlook for belantamab mafodotin, (known as Blenrep for short), the drug giant's treatment for the blood disease myeloma.